Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07399951 · ClinicalTrials.gov registry record · Early Phase 1
Washington University WU 409: Immune Responses to Rabies Vaccine.
A Early Phase 1 study of Healthy Participants, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07399951: Completed Early Phase 1 study of Healthy Participants, sponsored by Washington University School of Medicine.
NCT07399951 is a Early Phase 1 study of Healthy Participants that has completed, run by Washington University School of Medicine. The registered enrollment target is 30 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07399951, a Early Phase 1 study of Healthy Participants, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the immune response to rabies vaccination persons 18 years and older. We will evaluate thirty healthy participants across three cohorts: 1) standard rabies pre-exposure prophylaxis regimen (two doses of Imovax® or RabAvert® seven days apart with no RIG); 2) rabies pre-exposure prophylaxis regimen + day 0 RIG (two doses of Imovax® or RabAvert® seven days apart, with RIG administered at day 0); 3) rabies pre-exposure prophylaxis regimen + day 28 RIG (two doses of Imovax® or RabAvert® seven days apart, with RIG administered at day 28).
Primary Outcome
Neutralizing Rabies Virus Antibody Titers at D28
Conditions Studied
Interventions
- DRUG Imovax
- DRUG RabAvert
- DRUG HyperRAB
Study Locations (1)
Missouri
- Washington University School of Medicine Infectious Disease Clinical Trials Unit. - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-07-18 |
| Est. Completion | 2025-10-01 |
| Phase | Early Phase 1 |
What the finished NCT07399951 record still lists
NCT07399951 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 3 interventions - of which Imovax is the first listed.
NCT07399951 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT07399951 about?
NCT07399951 is a clinical study titled "Washington University WU 409: Immune Responses to Rabies Vaccine.". This study will evaluate the immune response to rabies vaccination persons 18 years and older. We will evaluate thirty healthy participants across three cohorts: 1) standard rabies pre-exposure prophylaxis regimen (two doses of Imovax® or RabAvert® seven days apart with no RIG); 2) rabies pre-exposu...
What is the current status of trial NCT07399951?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2023-07-18. Estimated completion is 2025-10-01.
What conditions does trial NCT07399951 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT07399951?
The interventions under investigation include: Imovax (DRUG), RabAvert (DRUG), HyperRAB (DRUG).
Who is sponsoring clinical trial NCT07399951?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07399951 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07399951's enrollment target sits among peer trials
30 72nd of 119 higher than 45 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
RECRUITING · Early Phase 1
-
Researching Economical Adjuvants to Cancer Therapy
RECRUITING · Early Phase 1
-
Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia
RECRUITING · Early Phase 1
-
Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration
COMPLETED · Early Phase 1
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI